TBPH Stock Recent News

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President and Chief Business Officer Rick Graham – Senior Vice President-Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Ben Ricard – Needham & Company David Risinger – SVB Securities Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2022 Conference Call.

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

DUBLIN , April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET (10:30 am PT/6:30 pm IST). A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events.

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

Theravance Biopharma Inc (NASDAQ: TBPH) revealed results from the second Phase 3 study assessing ampreloxetine compared to placebo for symptomatic nOH.  Neurogenic orthostatic hypotension (nOH) is a rare disorder defined as a sustained orthostatic fall in blood pressure within.

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistically significant for the overall population of patients. The overall population .